230 related articles for article (PubMed ID: 37487144)
1. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003916. PubMed ID: 22513918
[TBL] [Abstract][Full Text] [Related]
3. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy.
León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T;
J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941
[TBL] [Abstract][Full Text] [Related]
4. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant radiotherapy for stage I endometrial cancer.
Kong A; Johnson N; Kitchener HC; Lawrie TA
Cochrane Database Syst Rev; 2012 Mar; (3):CD003916. PubMed ID: 22419290
[TBL] [Abstract][Full Text] [Related]
6. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG; Creutzberg CL; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; van der Steen-Banasik EM; Mens JWM; Slot A; Kroese MCS; van Triest B; Nijman HW; Stelloo E; Bosse T; de Boer SM; van Putten WLJ; Smit VTHBM; Nout RA;
Br J Cancer; 2018 Oct; 119(9):1067-1074. PubMed ID: 30356126
[TBL] [Abstract][Full Text] [Related]
7. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
Creutzberg CL; van Stiphout RG; Nout RA; Lutgens LC; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):530-9. PubMed ID: 25680597
[TBL] [Abstract][Full Text] [Related]
8. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma--a prospective randomized study.
Sorbe B; Horvath G; Andersson H; Boman K; Lundgren C; Pettersson B
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1249-55. PubMed ID: 21676554
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Chemotherapy and Vaginal Vault Brachytherapy With or Without Pelvic Radiotherapy for Stage 1 Papillary Serous or Clear Cell Endometrial Cancer.
Tétreault-Laflamme A; Nguyen-Huynh TV; Carrier JF; Samouëlian V; Sauthier P; Beauchemin MC; Barkati M
Int J Gynecol Cancer; 2016 Feb; 26(2):301-6. PubMed ID: 26745699
[TBL] [Abstract][Full Text] [Related]
10. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract][Full Text] [Related]
11. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.
Harkenrider MM; Block AM; Alektiar KM; Gaffney DK; Jones E; Klopp A; Viswanathan AN; Small W
Brachytherapy; 2017; 16(1):95-108. PubMed ID: 27260082
[TBL] [Abstract][Full Text] [Related]
12. Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?
Wang CJ; Christie A; Folkert MR; Xie XJ; Albuquerque K
J Gynecol Oncol; 2018 Jul; 29(4):e49. PubMed ID: 29770620
[TBL] [Abstract][Full Text] [Related]
13. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
[TBL] [Abstract][Full Text] [Related]
14. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
15. Practice patterns of adjuvant radiotherapy in women with stage I to II endometrial carcinoma: a real-world multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Womens Health; 2023 Aug; 23(1):417. PubMed ID: 37553639
[TBL] [Abstract][Full Text] [Related]
16. The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.
Lee JK; Ghanem AI; Modh A; Burmeister C; Mahmoud O; Maxwell GL; Elshaikh MA
Brachytherapy; 2018; 17(2):319-325. PubMed ID: 29174935
[TBL] [Abstract][Full Text] [Related]
17. Treatment optimization of pelvic external beam radiation and/or vaginal brachytherapy for patients with stage I to II high-risk Endometrioid adenocarcinoma: a retrospective multi-institutional analysis.
Wang W; Zou L; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Sun S; Jin M; Zhang F; Hou X; Wei L; Hu K
BMC Cancer; 2021 Jul; 21(1):774. PubMed ID: 34217240
[TBL] [Abstract][Full Text] [Related]
18. TCGA molecular subgroups of endometrial carcinoma in ovarian endometrioid carcinoma: A quantitative systematic review.
D'Alessandris N; Travaglino A; Santoro A; Arciuolo D; Scaglione G; Raffone A; Inzani F; Zannoni GF
Gynecol Oncol; 2021 Nov; 163(2):427-432. PubMed ID: 34446267
[TBL] [Abstract][Full Text] [Related]
19. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
van den Heerik ASVM; Horeweg N; Nout RA; Lutgens LCHW; van der Steen-Banasik EM; Westerveld GH; van den Berg HA; Slot A; Koppe FLA; Kommoss S; Mens JWM; Nowee ME; Bijmolt S; Cibula D; Stam TC; Jurgenliemk-Schulz IM; Snyers A; Hamann M; Zwanenburg AG; Coen VLMA; Vandecasteele K; Gillham C; Chargari C; Verhoeven-Adema KW; Putter H; van den Hout WB; Wortman BG; Nijman HW; Bosse T; Creutzberg CL
Int J Gynecol Cancer; 2020 Dec; 30(12):2002-2007. PubMed ID: 33046573
[TBL] [Abstract][Full Text] [Related]
20. Endometrial Cancer: Transitioning from Histology to Genomics.
Mitric C; Bernardini MQ
Curr Oncol; 2022 Jan; 29(2):741-757. PubMed ID: 35200562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
